Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 01:30:00 15/05/2025 am IST			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

15/25/15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/25/15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	2.97Cr 2.62Cr 2.47Cr 2.25Cr 4.21Cr 285.51Cr 4.24Cr 30Cr 11Cr 145.31Cr 11Cr 11Cr 472.85Cr	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-4.69Cr -4.13Cr -3.89Cr -3.55Cr -6.64Cr -450.39Cr -6.69Cr -47Cr -18Cr -229.22Cr -18Cr -17Cr -745.91Cr	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

15/25/15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/25/15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
15/25/15	Allakos Inc. Announces Executive Changes	CI
15/25/15	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
15/25/15	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
09/25/09	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
08/25/08	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/25/02	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
02/25/02	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
02/25/02	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
13/25/13	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
13/25/13	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
28/25/28	Top Midday Decliners	MT

17/24/17	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
17/24/17	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
17/24/17	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
17/24/17	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
17/24/17	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Share Price

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news: Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

22/22/22	Lonza-Aktien sinken nach Halbjahreszahlen
05/19/05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
05/19/05	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/05/25	Steven James	Issuer sale	Director	3,32,932	0.3726%
15/05/25	Neil Graham	Issuer sale	Director	1,95,786	0.2191%
15/05/25	BVF Partners LP	Issuer sale	Company	1,63,12,872	18.2586%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-84.83%	2.97Cr
LONZA GROUP AG	+1.46%	+5.87%	+5.75%	+33.71%	4.76TCr
IQVIA HOLDINGS INC.	+2.67%	+2.31%	+47.50%	+38.37%	4.41TCr
BEONE MEDICINES AG	-1.38%	+3.42%	+9.39%	+88.88%	4.15TCr
REVOLUTION MEDICINES, INC.	+4.78%	+2.01%	+352.12%	+566.20%	4.09TCr
CELLTRION, INC.	-0.62%	+0.11%	+1.12%	+46.02%	2.97TCr
MEDPACE HOLDINGS, INC.	+0.56%	+0.67%	+25.08%	+155.71%	1.72TCr
EUROFINS SCIENTIFIC SE	+2.05%	+4.04%	+24.47%	+41.67%	1.51TCr
ASCENDIS PHARMA A/S	+3.39%	-6.86%	-	-	1.47TCr
TEMPUS AI, INC.	+7.38%	+17.54%	-2.25%	-	1.38TCr
Average	+1.99%	+0.62%	+51.47%	+110.72%	2.64TCr
Weighted average by Cap.	+1.88%	+0.96%	+71.87%	+147.46%

	2023	2024
Net sales	-	-
Net income	-19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -26Cr -184.78Cr -72Cr -907.24Cr -70Cr -68Cr -2.95TCr	-12Cr -10Cr -9.6Cr -8.76Cr -16Cr -1.11TCr -17Cr -115.24Cr -45Cr -565.83Cr -43Cr -43Cr -1.84TCr
Net Debt	-13Cr -11Cr -11Cr -9.78Cr -18Cr -1.24TCr -18Cr -128.69Cr -50Cr -631.83Cr -49Cr -48Cr -2.06TCr	-7.67Cr -6.74Cr -6.36Cr -5.8Cr -11Cr -735.9Cr -11Cr -76Cr -30Cr -374.53Cr -29Cr -28Cr -1.22TCr

3 years	0.22	3.4
5 years	0.22	112.87
10 years	0.22	157.98